MRC Technology and Proximagen Collaborate to Develop Novel Therapeutics for Inflammatory and Autoimmune Disease
![](/46/pdcnewsitem/03/37/57/SR9Iqn1VNQsfwrE.jpg)
MRC Technology and Proximagen Group Ltd have entered into collaboration to progress small molecules for the treatment of inflammatory and autoimmune disease. Proximagen is a UK-based biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and is owned by Upsher-Smith Laboratories, Inc., a Minnesota-based growing pharmaceutical company.
Applying MRC Technology’s medicinal chemistry expertise, the project will focus on the potential of the enzymatic cytokine, Macrophage migration inhibitory factor (MIF), as a key target and progress the research towards proof of concept in an animal model with future commercialisation potential.
MIF is a multipotent cytokine that has been implicated in the pathogenesis of numerous autoimmune inflammatory disorders. MRC Technology will investigate the therapeutic potential of the MIF inhibitors through proof of concept studies in animal models including efficacy, pharmacokinetic and toxicology data. This work will be done as a prelude to MRC Technology identifying commercial partnering opportunities for the project and subsequent progression towards the clinic.
Michael Dalrymple, Director of Business Development at MRC Technology commented: “This collaboration represents a new shared-risk model for us to meet our objective of pushing new healthcare discoveries towards the market, by working with companies to help progress their promising but less-prioritised projects. We are hopeful that this collaboration will lead to compounds with proof of efficacy ready for partnering with industry.”
“The selective inhibition of MIF has the potential to offer new therapeutic avenues for inflammatory and autoimmune disease,” commented Martyn Pritchard PhD, Head of R&D at Proximagen. “We are delighted to be working with MRC Technology and their expert team to further progress this important project.”
Financial terms of the agreement were not disclosed.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance